FDA approves new type of therapy to treat advanced urothelial cancer

December 18, 2019 – Today, the U.S. Food and Drug Administration granted accelerated approval to Enfortumab vedotin-ejfv, a Nectin-4-directed antibody and microtubule inhibitor conjugate, meaning the drug specifically targets cancer cells – in this case, the cell adhesion molecule Nectin-4, which is highly expressed in urothelial cancers. Padcev is indicated for the treatment of adult patients with locally advanced (when cancer has grown too large to be surgically … (leggi tutto)